
Administer 1.8 mg/kg by intramuscular injection up to a maximum dose of 900 mg per horse. Divide the total volume evenly into three separate injection sites. Discard unused vial contents. OSPHOS is provided in a single use vial and does not contain a preservative.
Clinical improvement is most evident at 2 months post-treatment (see Effectiveness). Of the horses that responded to treatment with OSPHOS in the field study, 65% maintained their level of improvement through the 6 month evaluation.
If there is no response to initial therapy, the horse should be re-evaluated. For horses that initially respond to OSPHOS but do not maintain their clinical improvement for 6 months, OSPHOS may be re-administered at 3 to 6 month intervals based on recurrence of clinical signs. For horses that respond to OSPHOS and maintain clinical improvement for 6 months, OSPHOS should be re-administered after clinical signs recur.